Related Experiment Video
Updated: Sep 28, 2025
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.1K
Abstract:
The KRASG12C inhibitor sotorasib was associated with a 21.1% objective response rate and an 84.2% disease control rate among patients who had already received at least one therapy for pancreatic ductal adenocarcinoma. These data come from the phase I/II CodeBreaK100 trial.
Insights
Sotorasib, a KRASG12C inhibitor, showed promising results in patients with pancreatic ductal adenocarcinoma previously treated with other therapies. The drug achieved a 21.1% objective response rate and an 84.2% disease control rate in the CodeBreaK100 trial.
Area of Science:
- Oncology
- Molecular targeted therapy
- Gastroenterology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) remains a challenging malignancy with limited treatment options.
- The KRAS G12C mutation is a common driver mutation in PDAC, representing a potential therapeutic target.
Purpose of the Study:
- To evaluate the efficacy and safety of sotorasib, a KRASG12C inhibitor, in patients with previously treated PDAC.
- To assess the objective response rate (ORR) and disease control rate (DCR) of sotorasib in this patient population.
Main Methods:
- Phase I/II clinical trial (CodeBreaK100).
- Inclusion of patients with advanced PDAC who had received at least one prior therapy.
- Administration of sotorasib as a targeted therapy.
Main Results:
- Sotorasib demonstrated an objective response rate (ORR) of 21.1% among patients with previously treated PDAC.
- A disease control rate (DCR) of 84.2% was observed, indicating tumor stabilization in a significant portion of patients.
- Safety and tolerability data were also collected as part of the trial.
Conclusions:
- Sotorasib exhibits significant anti-tumor activity in patients with KRAS G12C-mutated pancreatic ductal adenocarcinoma.
- These findings support sotorasib as a potential treatment option for patients with advanced PDAC who have progressed on prior therapies.
- Further investigation in larger trials is warranted to confirm these promising results.
Related Concept Videos
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:22PI3K/mTOR/AKT Signaling Pathway
4.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.1K
01:03Rous Sarcoma Virus (RSV) and Cancer
5.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.5K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K